We show that targeting apre-resistance signature gene G1 to S phase transition 1 (GSPT1)with a selective degrader (CC-90009) exhibits strong synergy when combined with FLT3inhibitors in FLT3-ITD-mutated AML cell lines and primary patient samples. The gene discussed is FLT3; the disease is acute myeloid leukemia.